CA2290974C - Solubilized sertraline compositions - Google Patents

Solubilized sertraline compositions Download PDF

Info

Publication number
CA2290974C
CA2290974C CA002290974A CA2290974A CA2290974C CA 2290974 C CA2290974 C CA 2290974C CA 002290974 A CA002290974 A CA 002290974A CA 2290974 A CA2290974 A CA 2290974A CA 2290974 C CA2290974 C CA 2290974C
Authority
CA
Canada
Prior art keywords
composition
sertraline
matter
solubilizing agent
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002290974A
Other languages
English (en)
French (fr)
Other versions
CA2290974A1 (en
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2290974(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CA2290974A1 publication Critical patent/CA2290974A1/en
Application granted granted Critical
Publication of CA2290974C publication Critical patent/CA2290974C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
CA002290974A 1997-07-01 1998-06-15 Solubilized sertraline compositions Expired - Fee Related CA2290974C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
US60/051,413 1997-07-01
PCT/IB1998/000933 WO1999001120A1 (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Publications (2)

Publication Number Publication Date
CA2290974A1 CA2290974A1 (en) 1999-01-14
CA2290974C true CA2290974C (en) 2004-04-27

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290974A Expired - Fee Related CA2290974C (en) 1997-07-01 1998-06-15 Solubilized sertraline compositions

Country Status (34)

Country Link
EP (1) EP0999829A1 (ru)
JP (1) JP2000514100A (ru)
KR (1) KR100366373B1 (ru)
CN (1) CN1261794A (ru)
AP (1) AP1192A (ru)
AR (3) AR015917A1 (ru)
AU (1) AU742535B2 (ru)
BG (1) BG103918A (ru)
BR (1) BR9810739A (ru)
CA (1) CA2290974C (ru)
CO (1) CO4940495A1 (ru)
DZ (1) DZ2548A1 (ru)
EA (1) EA002481B1 (ru)
HN (1) HN1998000102A (ru)
HR (1) HRP980377A2 (ru)
HU (1) HUP0002236A3 (ru)
ID (1) ID23429A (ru)
IL (1) IL133076A (ru)
IS (1) IS5260A (ru)
MA (1) MA24587A1 (ru)
NO (1) NO996520L (ru)
OA (1) OA11243A (ru)
PA (1) PA8454301A1 (ru)
PE (1) PE97199A1 (ru)
PL (1) PL337804A1 (ru)
SK (1) SK181099A3 (ru)
TN (1) TNSN98124A1 (ru)
TR (1) TR199903297T2 (ru)
TW (1) TW550087B (ru)
UA (1) UA67741C2 (ru)
UY (1) UY25071A1 (ru)
WO (1) WO1999001120A1 (ru)
YU (1) YU68299A (ru)
ZA (1) ZA985708B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
WO2008110268A1 (en) * 2007-03-12 2008-09-18 Dsm Ip Assets B.V. Cosmetic compositions
WO2011081117A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用固形医薬組成物
KR20120116422A (ko) * 2009-12-29 2012-10-22 코와 가부시키가이샤 경구 투여용 의약 조성물
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE69004529T2 (de) * 1989-08-30 1994-02-24 Pfizer Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
EA002481B1 (ru) 2002-06-27
UY25071A1 (es) 2000-12-29
SK181099A3 (en) 2000-07-11
AP9801280A0 (en) 1998-06-30
KR20010013365A (ko) 2001-02-26
DZ2548A1 (fr) 2003-02-08
HN1998000102A (es) 1999-01-08
MA24587A1 (fr) 1998-12-31
TR199903297T2 (xx) 2000-07-21
EP0999829A1 (en) 2000-05-17
IL133076A (en) 2003-12-10
CA2290974A1 (en) 1999-01-14
YU68299A (sh) 2002-06-19
CN1261794A (zh) 2000-08-02
IL133076A0 (en) 2001-03-19
HUP0002236A2 (hu) 2003-08-28
EA199900962A1 (ru) 2000-08-28
WO1999001120A1 (en) 1999-01-14
IS5260A (is) 1999-11-19
AR040279A2 (es) 2005-03-23
CO4940495A1 (es) 2000-07-24
AR040280A2 (es) 2005-03-23
PA8454301A1 (es) 2000-09-29
OA11243A (en) 2003-07-24
AU7544898A (en) 1999-01-25
HRP980377A2 (en) 1999-04-30
BG103918A (en) 2000-07-31
AR015917A1 (es) 2001-05-30
AP1192A (en) 2003-07-23
HUP0002236A3 (en) 2003-12-29
NO996520D0 (no) 1999-12-28
UA67741C2 (ru) 2004-07-15
PE97199A1 (es) 1999-10-05
PL337804A1 (en) 2000-09-11
JP2000514100A (ja) 2000-10-24
KR100366373B1 (ko) 2003-01-14
ID23429A (id) 2000-04-20
AU742535B2 (en) 2002-01-03
TNSN98124A1 (fr) 2005-03-15
BR9810739A (pt) 2000-09-12
TW550087B (en) 2003-09-01
NO996520L (no) 2000-02-29
ZA985708B (en) 2000-01-10

Similar Documents

Publication Publication Date Title
JP3382950B2 (ja) 医薬品用の徐放性マトリックス
US5670171A (en) Liquid-suspension controlled-release pharmaceutical composition
US4772473A (en) Nitrofurantoin dosage form
ES2405404T3 (es) Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
KR20010012857A (ko) 개선된 약물 전달용 위장체류 방출조절 미소립자
PT1492511E (pt) Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
JP2010163455A (ja) 活性成分放出制御薬物製剤
JP2003513882A (ja) ジバルプロエックスナトリウムの制御放出製剤
JPH04210919A (ja) ピモベンダン経口投与製剤
RU2237480C2 (ru) Непосредственно прессуемая матрица для регулируемого высвобождения однократных ежедневных доз кларитромицина
PT1492531E (pt) Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas que permite a libertação modificada de amoxicilina
ES2852899T3 (es) Formulaciones estabilizadas de molindona
CA2290974C (en) Solubilized sertraline compositions
US7063864B1 (en) Morphine sulphate microgranules, method for preparing same and compositions containing same
EP3288549A1 (en) Oral liquid compositions of guanfacine
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
WO2020157730A1 (en) A controlled release pharmaceutical composition of selexipag or it's active metabolite
AU7545198A (en) Delayed-release dosage forms of sertraline
JP2002509887A (ja) セファクロル含有徐放性組成物
JPH069388A (ja) 徐放性塩酸オキシブチニン製剤
JPH0748256A (ja) ニセルゴリンを含有する制御放出性の製薬組成物
PT1618873E (pt) Grânulos para libertação controlada de tamsulosina, que contém alginato.
US20040208926A1 (en) Solubilized sertraline compositions
NZ501250A (en) Solubilized sertraline compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed